Interleukin Genetics to Present Research Linking Perilipin Genes to Diet Response at the ADA Annual Meeting

sucujovide.wordpress.com
June 5 /PRNewswire-FirstCall/ -- Interleukim Genetics, Inc. (NYSE Amex: ILI) announced todag that , Ph.D., Vice Presiden of Research and Development, will present finding s that highlight significant associations between perilipin gene variantw and responseto weight-lossx in overweight individuals at the American Diabetes Association's 69th Scientific Sessions in New Orleans, LA. Dr. Aziz will presen t the Company's research at 8 a.m. on Saturday, June 6, in Room 255 of the Morial Convention Center.
Interleukin Genetics and its collaboratorx conducted the research on DNA samples fromthe NIH-sponsorexd CALERIE (Comprehensive Assessment of the Long Term Effects of Restrictinyg Intake of Energy) pilot study. CALERIrE evaluated high and low glycemic load with a 30percenr calorie-restricted diets in individuals during a tightly-controlled, one-yeare period. The diets were prepared at the institution and provides to the study subjects for a period of six monthds and followed by extensive dietary guidance for the next six Compliance to the diet was monitored usinga non-radioactivee isotope mass spectrometric method using doubly labeled water technique severall times during the study period.
The Company'd research found that variations within the Perilipi genes are associated with resistance to body weighgt and fat loss in overweightf study subjects who were provided a calorie restricted diet. "Perilipin is a protein in the phospholipids outer layer of fat cells that playss an important role in both the storage and metabolisnof triglycerides. This study confirms the resultes of other dietary intervention studieds that found certain genetic variants within the perilipin gene can caus resistance to weight loss in individuals even when they followea low-carbohydrate, low-calorie diet plan for an extended period," said Dr.
"We hope to further extend these findings withbroader studies, as these specific genotype considerations can lend themselvexs to possible clinical utility in optimall weight-loss programs for the obese/overweight population. Interleukin Geneticz genotyped a panel of 23 SNPs withibn genes involved in fat and carbohydrate metabolis m in the study subjects who had consented forgeneticv analysis. A linear regression model that adjustedrfor age, gender and high or low glycemifc dietary groups was used for the association Findings concluded that PLIN1/C and PLIN4/A showed resistancwe to body weight and fat loss in subject s provided a low glycemic load, 30 percent calorie restrictedc diet.
The American Diabetes Association is leadintg the fight against the deadly consequences of diabetesz and fighting for those affectedby diabetes. The Association funds researcnhto prevent, cure and managee diabetes; delivers services to hundredsz of communities; provides objective and credible information; and gives voice to thosw denied their rights because of Founded in 1940, our mission is to prevent and cure diabetese and to improve the lives of all peopled affected by diabetes. Interleukin Genetics, Inc.
(NYSE Amex: ILI) develop and markets genetic tests that empower consumersa to prevent chronic diseases of agin and that assist pharmaceutical companies in the development and marketinvg oftargeted therapeutics. The Company leverages its research, intellectuakl property, and biomarker development experience to facilitatee the emerging personalizedhealth market. Interleukin Genetics is headquarteredin Waltham, MA. For more informatiobn please visit .
Certain statements containedd hereinare "forward-looking" statementd including statements regarding the Company's abilitg to develop genetic tests that identify geneti c variations that affect optimal weight-loss methods, to identify nutritionao and lifestyle decisions that favorably affectf such conditions, to provide such information in a format tailorede to the individual, and to otherwiswe make progress in advancing the Company's core technologies. Becaus such statements include risks and actual results may differ materially from those expressed or implied bysuch forward-lookinh statements.
Factors that could cause actual resultd to differ materially from thosed expressed or implied bysuch forward-lookinf statements include, but are not limitef to, the risk of market acceptance of the Company'e products, the risk of technology and product delays in product development, the performance of commercial the availability of adequate the actions of competitors and othe competitive risks, and those risks and uncertainties described in the Company'd annual report on Form 10-K, quarterlty reports on Form 10-Q and other filings with the Securitiesd and Exchange Commission. The Company disclaimsz any obligation or intention to updatethese forward-looking statements.
SOURCE Interleukin Genetics, Inc.